Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.81% |
| 2 | Technology | 15.51% |
| 3 | Consumer Discretionary | 11.84% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3601
Key Tronic
KTCC
$42.8M
| $106K | ﹤0.01% |
24,400
+7,573
| +45% | +$34.5K |
|
|
TTNP
3602
DELISTED
Titan Pharmaceuticals
TTNP
| $105K | ﹤0.01% |
6,721
-515
| -7% | -$9.74K |
|
3603
Asia Pacific Wire & Cable
APWC
$61.8M
| $104K | ﹤0.01% |
72,000
-7,000
| -9% | -$9.07K |
|
3604
Ebang International Holdings
EBON
$12.3M
| $104K | ﹤0.01% |
35,613
+1,776
| +5% | +$13.1K |
|
3605
Gain Therapeutics
GANX
$92.6M
| $104K | ﹤0.01% |
33,200
-200
| -0.6% | -$625 |
|
3606
CareCloud
CCLD
$104M
| $103K | ﹤0.01% |
36,500
+600
| +2% | +$2.07K |
|
|
ZSTK
3607
ZeroStack Corp
ZSTK
$21.1M
| $103K | ﹤0.01% |
580
+220
| +61% | +$81.7K |
|
|
VIP
3608
Vulcan Infrastructure and Power Inc. Class A Common Stock
VIP
$32.5M
| $103K | ﹤0.01% |
35,645
+4,765
| +15% | +$37.9K |
|
3609
Direct Digital Holdings
DRCT
$2.05M
| $102K | ﹤0.01% |
191
+131
| +218% | +$75.7K |
|
3610
Entera Bio
ENTX
$138M
| $102K | ﹤0.01% |
139,600
+118,300
| +555% | +$85.6K |
|
3611
Veritone
VERI
$139M
| $102K | ﹤0.01% |
19,200
-16,700
| -47% | -$107K |
|
|
CZOO
3612
DELISTED
Cazoo Group Ltd
CZOO
| $102K | ﹤0.01% |
324
+164
| +103% | +$97.1K |
|
|
SRGA
3613
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $102K | ﹤0.01% |
51,452
-7,218
| -12% | -$17.8K |
|
|
SPI
3614
DELISTED
SPI Energy Co., Ltd. Ordinary Shares
SPI
| $102K | ﹤0.01% |
118,966
+37,584
| +46% | +$49.4K |
|
3615
Redwire
RDW
$3.3B
| $101K | ﹤0.01% |
51,200
+19,000
| +59% | +$43.8K |
|
3616
Cadiz
CDZI
$292M
| $100K | ﹤0.01% |
+39,900
| New | +$83.1K |
|
3617
Xilio Therapeutics
XLO
$59.6M
| $100K | ﹤0.01% |
2,650
+614
| +30% | +$20.7K |
|
|
ADAG
3618
Adagene
ADAG
$248M
| $99K | ﹤0.01% |
74,600
-21,200
| -22% | -$24.2K |
|
3619
Elicio Therapeutics
ELTX
$82.7M
| $99K | ﹤0.01% |
12,170
-8,728
| -42% | -$79.3K |
|
|
FENG
3620
Phoenix New Media
FENG
$18.9M
| $99K | ﹤0.01% |
36,931
-11,200
| -23% | -$42K |
|
|
SLNO
3621
DELISTED
Soleno Therapeutics
SLNO
| $99K | ﹤0.01% |
49,754
+4,800
| +11% | +$5.97K |
|
3622
Summit Therapeutics
SMMT
$11.2B
| $99K | ﹤0.01% |
+23,300
| New | +$42.4K |
|
|
AXIA.PR
3623
DELISTED
AXIA Energia American Depositary Shares Preferred Class B1
AXIA.PR
| $98K | ﹤0.01% |
15,114
-31,106
| -67% | -$226K |
|
3624
Quince Therapeutics
QNCX
$31.8M
| $98K | ﹤0.01% |
771
-900
| -54% | -$151K |
|
3625
TMC The Metals Company
TMC
$1.91B
| $98K | ﹤0.01% |
127,900
+13,900
| +12% | +$12K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.